More on CRVO
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $3.34 |
|
|||
| Open | $3.26 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $3.36 | ||||
| Day Low | $3.13 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 309,462 | ||||
- H.C. Wainwright Reiterates Buy Rating on CervoMed (CRVO)
- Form 8-K CervoMed Inc. For: Sep 28
- CervoMed reports new neflamapimod tablet data, FDA lifts exposure cap
- CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit
- CervoMed to Participate in the 5th Annual ROTH Healthcare Opportunities Conference
- Form 8-K CervoMed Inc. For: Sep 10
- CervoMed nfvPPA trial data to be presented at ISFTD meeting
- CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFT
- CervoMed to Participate in September Investor Conferences
- Form SCHEDULE 13G/A CervoMed Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Entities mentioned with CRVO
- FDA | View Related Stories »
- Definitive Agreement | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- 13G | View Related Stories »
- H.C. Wainwright | View Related Stories »
- Earnings | View Related Stories »
- Show More...
